ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1722

Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy

Peter Gorevic1, Frank Eng 2, Andrea Branch 3, Ahmed Elshamy 4, Erin Doyle 2 and Thomas Schiano 2, 1Mount Sinai Hospital, New York, 2Mount Sinai Medical Center, New York, 3Mount Sinai Medical School, New York, 4California Northstate University, Sacramento

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Cryoglobulinemia, Hepatitis C and immune complex, proteomics, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: BACKGROUND. Mixed Cryoglobulins (MCs) are cold precipitable Rheumatoid Factors (RFs) that provide a biomarker for immune complex formation, particularly associated with chronic Hepatitis C Virus (HCV) and Cryoglobulinemic Vasculitis (CryoVas) syndromes. Both the IgM and IgG components of MCs may span a spectrum of clonality, in type 2 >95% being IgMk and bearing Cross-reactive Idiotypes (CRIs) that can be revealed antigenically or by assessing specific heavy and/or light chain V-gene usage. Older studies indicated that C1q may be an integral part of MCs and that up to a third of the protein content is nonimmunoglobulin.

 

OBJECTIVES. We aimed to define the Immune Complexome of MCs by Mass Spectroscopy and protein sequence analysis (MALDI TOF) compared to existing data bases

Methods: METHODS MCs were isolated from the sera of patients with (a) HCV/CroVas before and after clearance of virus by Direct Acting Antivirals (DAAs), (b) persistent disease (purpura, nephritis) 2-15 years after HCV cure; (c) HIV-HCV coinfection, and (d) sjogrens or lupus patients with MCs consistently negative for HCV RNA . Isolated MCs were characterized by immunofixation and gel electrophoresis (SDS-PAGE) before being processed for MALDI-TOF. Specific gel bands identified by SDS-PAGE, including the IgM heavy chain, were excised and sequenced. In addition, serum obtained before cryoprecipitation was analyzed for the three pathways of complement activation and k/l by free and heavy-light chain immunoassays.

Results: RESULTS In a prospective clinical trial (NTC0282512) the prevalence of complement abnormalities and an expansion of k light chains was demonstrated and the short-term effects of DAA, as well as SVR 24 were analyzed to assess biomarkers concomitant with viral clearance from blood and cryoprecipitates. Depression of C4/C1q was particularly apparent among the patients with persistent cryoglobulinemia, along with IgMk clonality. The validity of MALDI-TOF was reflected in the abundance of Ig heavy and light chain sequences, IgG subclasses, k/l ratios, V-region subgroups, and MC/monoclonal RF VH1-69, VH3-30, VK3D-15 and VK3D-20 MC CRI protein sequences In addition, complement (notably C1q) co-associated with the MC Igs, as well as other proteins relevant to known phlogistic activities of MCs, binding of IgM and the aggregation of proteins in the cold.

Conclusion: CONCLUSIONS Our studies provide a platform for the analysis of MC immune complex proteomics as a laboratory biomarker relevant to CryoVas clinical syndromes


Disclosure: P. Gorevic, None; F. Eng, None; A. Branch, None; A. Elshamy, None; E. Doyle, None; T. Schiano, None.

To cite this abstract in AMA style:

Gorevic P, Eng F, Branch A, Elshamy A, Doyle E, Schiano T. Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/mixed-cryoglobulin-immune-complex-proteomics-analysis-by-mass-spectroscopy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mixed-cryoglobulin-immune-complex-proteomics-analysis-by-mass-spectroscopy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology